ERG is a selective dependency in EVI1-driven AML. Competitive proliferation assays, showing as the percentage of IRFP670-positive cells expressing indicated shRNAs over time. Nontargeting shRen.713 and essential shMYC.1835 were used as negative and positive controls, respectively (mean ± SD; n = 3). (A) Competitive proliferation assay using human AML cell lines. (B) Competitive proliferation assay using RUNX1/EVI1-driven vs MLL/AF9-driven murine leukemia cells. (C) Flow cytometric analyses of murine RUNX1/EVI1-driven leukemia cells 7 days post Dox-mediated shRNA induction (mean ± SD; n = 3). Quantification of c-Kit and Mac-1 surface marker expression. (D) Representative cytospin images of purified murine RUNX1/EVI1-driven leukemia cells expressing indicated shRNAs 10 days post Dox-mediated shRNA induction. (E) Flow cytometric analyses of murine RUNX1/EVI1-driven leukemia cells 7 days post Dox-mediated shRNA induction (mean ± SD; n = 3). Quantification of annexin V-positive cells.